Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 1-Year High – Time to Buy?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $14.55 and last traded at $14.11, with a volume of 1491914 shares changing hands. The stock had previously closed at $13.58.

More Bayer Aktiengesellschaft News

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Settlement could deliver legal closure that removes long‑running litigation over Roundup, which would reduce future legal uncertainty for Bayer if approved. Explainer: Will Bayer’s proposed $7.25 billion Roundup deal bring legal closure?
• Positive Sentiment: Bayer says the U.S. executive order to boost glyphosate supply is not expected to cause shortages outside the U.S., easing worries about global product availability and supply‑chain disruption. Bayer: glyphosate shortages not expected outside the US after executive order
• Neutral Sentiment: Shares briefly jumped on heavy volume in the prior session, but at least one note warns that recent estimate revisions don’t imply sustained upside. Short‑term volatility is likely as news continues to flow. Bayer (BAYRY) Surges 6.0%: Is This an Indication of Further Gains?
• Neutral Sentiment: Company and market analysts are discussing the settlement’s structure and implications in detail (transcripts and deep dives available), which will drive investor focus on funding, timing and legal releases. Bayer discusses Roundup class settlement agreement and implications
• Negative Sentiment: Analyst downgrade: DZ Bank cut Bayer from “strong‑buy” to “strong sell,” adding selling pressure and signaling renewed negative analyst sentiment. DZ Bank downgrade reported via Zacks
• Negative Sentiment: Market skepticism about the settlement’s size and effectiveness is widespread; coverage notes doubts the $7–10.5B figures will fully resolve all risk, which is weighing on investor confidence. Bayer’s $7 Billion Bid to End Roundup Curse Draws Skepticism
• Negative Sentiment: Immediate market reaction: reports show the stock fell sharply after Bayer disclosed the preliminary settlement plan, reflecting investor concern about the cash cost and near‑term hit to sentiment. Bayer falls after proposing $7.25 billion settlement

Analysts Set New Price Targets

Several research analysts recently issued reports on BAYRY shares. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. DZ Bank lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research note on Wednesday. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Finally, Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bayer Aktiengesellschaft currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

The company’s 50-day moving average is $12.08 and its 200-day moving average is $9.56. The firm has a market capitalization of $52.19 billion, a price-to-earnings ratio of 9.18, a PEG ratio of 4.77 and a beta of 0.68. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.